Ocular Therapeutix™ Announces FDA Agreement to Amend Special Protocol Assessment (SPA) for Pivotal Clinical Trial of AXPAXLI™ in Wet AMD

January 25, 2024

https://www.globenewswire.com/news-release/2024/01/25/2816690/0/en/Ocular-Therapeutix-Announces-FDA-Agreement-to-Amend-Special-Protocol-Assessment-SPA-for-Pivotal-Clinical-Trial-of-AXPAXLI-in-Wet-AMD.html

SPA amendment expands eligibility criteria for SOL clinical trial

Broadening of eligibility criteria anticipated to accelerate overall trial enrollment

Read more at globenewswire.com

Related news for (OCUL)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.